DUBLIN, Sept. 13, 2018 /PRNewswire/ --
The "Global Metastatic Cancer Treatment Market - Focus on Drugs, Competitive Landscape, and Country - Analysis and Forecast (2018-2025)" report has been added to ResearchAndMarkets.com's offering.
The global metastatic cancer treatment market was valued $54.11 billion in 2017, and is anticipated to reach $98.24 billion by 2025
Rising prevalence of cancer disease around the world and high unmet medical needs of patients suffering from metastatic cancer are the drivers stimulating the growth of the metastatic cancer treatment market. In addition, increasing adoption of biologics and biosimilars and ascending approvals from regulatory bodies, are contributing to the rising use of biologics for the treatment of metastatic cancer.
The purpose of the study is to gain a holistic view of the global metastatic cancer treatment market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, scientific innovations into oncology fields, etc. The scope of the report is centered upon conducting a detailed study of the solutions allied with metastatic cancer treatment market, which involves drugs used in different therapeutic applications for cancer treatment such as chemotherapy, hormone therapy, and immunotherapy, among others.
The global metastatic cancer treatment market is segmented into three different parts: by products', by therapeutic indication', and by region'. The global market value for metastatic cancer was estimated using these three different approaches and was validated with one another. These segments are further segmented into several sub-segments to ease the market estimation.
Based on products, the market can be sub-segmented into branded medicines and generic medicines. The market for branded medicines, in terms of revenue, far exceeds the market of generic medicines. The growth of the branded medicine market is accredited to the rising demand for advanced oncology medicines along with increase in the research and development facilities globally. However, generic medicine market exhibits much higher growth rate due to the patent expiry of branded drugs and availability of cancer treatment drugs at an affordable price. The presence of the same active substance in generic drugs, which are as safe and effective as their brand-name counterparts is the major advantage of generic medicines.
Based on therapeutic indication, the market can be classified into six major cancer types, which include breast cancer, melanoma, lung cancer, prostate cancer, colorectal cancer, and others. Among the different types of cancers, breast cancer is the leading contributor of metastatic cancer treatment market, while the highest CAGR is registered by melanoma during the forecast period from 2018 to 2025.
Geographically, the market is sub-segmented into five distinct regions including, North America, Europe, Asia-Pacific, Latin America, and Rest of the World. North America, followed by Europe, is the leading contributor of the market. Within North America, the U.S. contributed for almost 95% of the total share, and the rest was occupied by Canada in 2017. Within Europe, Germany dominated the market in 2017. However, the market for Asia-pacific region is expected to demonstrate high growth rate, during the forecast period from 2018 to 2025, as compared to other regions, and the region holds a strong potential for market expansion in the future.
The metastatic cancer treatment market has a promising potential for growth in the coming years. The report provides an in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each company.
Key Topics Covered:
1 Market Overview
1.1. Introduction to Cancer
1.2. Cancer Statistics: Incidence, Survival and Mortality
1.2.1. Important Facts
1.3. Metastasis and Metastatic Cancer
1.3.1. Where Cancer Spreads
1.3.1. Ongoing Research and Treatment of Metastatic Cancer
1.4. Global Market
1.5. FDA Approvals of Oncology Drugs
1.6. Assumptions and Limitation
2 Market Dynamics
2.1. Market Dynamics: Impact Analysis
2.2. Market Drivers
2.3. Market Restraints
2.4. Market Opportunities
3 Industry Insights
3.2. Regulatory Scenario
3.3. Regulatory Designations
3.4. Patent Landscape
4 Competitive Landscape
4.2. Key Developments and Strategies
4.2.1. Product Approvals
4.2.2. Clinical Study
4.2.3. Agreement, Partnership, Joint Venture and Collaboration
4.2.4 Regulatory Designations
4.2.5. Acquisition, Product Launches and Others
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrant
4.3.4. Threat of Substitute
4.3.5. Intensity of Competitive Rivalry
4.4. Market Share (2014-2017)
4.5. Pipeline Analysis
5 Global Metastatic Cancer Treatment Market, By Therapeutic Application
5.2. Breast Cancer
5.2.1. Breast Cancer: Types, Secondary Sites and Symptoms
184.108.40.206. Breast Cancer: Molecular Subtypes
5.2.2. Breast Cancer: Incidence, Mortality and Prevalence
5.2.3 Breast Cancer: Market
5.2.4. Breast Cancer: Treatment
5.3.1. Melanoma: Types, Secondary Sites and Symptoms
5.3.2. Melanoma: Incidence, Mortality and Prevalence
5.3.3 Melanoma: Market
5.3.4. Melanoma: Treatment
5.4. Prostate Cancer
5.4.1. Prostate Cancer: Types, Secondary Sites and Symptoms
5.4.2. Prostate Cancer: Incidence, Mortality and Prevalence
5.4.3. Prostate Cancer: Market
5.4.4. Prostate Cancer: Treatment
5.5. Lung Cancer
5.5.1. Lung Cancer: Types, Secondary Sites and Symptoms
5.5.2. Lung Cancer: Incidence, Mortality and Prevalence
5.5.3. Lung Cancer: Market
5.5.4. Lung Cancer: Treatment
5.6. Colorectal Cancer
5.6.1. Colorectal Cancer: Types, Secondary Sites and Symptoms
5.6.2. Colorectal Cancer: Incidence, Mortality and Prevalence
5.6.3. Colorectal Cancer: Market
5.6.4. Colorectal Cancer: Treatment
5.7. Other Cancers
6 Global Metastatic Cancer Treatment Market, By Product
6.1.1. Generic vs. Branded Drugs
6.2. Role of Branded Medicines in Oncology
6.2.1. Branded Medicines: Market
6.3. Role of Generic Medicines in Oncology
6.3.1. Generic Medicines: Market
6.4. Sales of Oncology Drugs
7 Global Metastatic Cancer Treatment Market, By Region
8 Company Profiles
- AbbVie, Inc.
- Amgen, Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- BRISTOL-MYERS SQUIBB COMPANY
- CELGENE CORPORATION
- Eli-Lilly and Company
- F. Hoffmann-La Roche AG
- JOHNSON & JOHNSON
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- bluebird bio, Inc.
- Clovis Oncology, Inc.
- IDERA PHARMACEUTICALS, INC.
- eTheRNA immunotherapies NV
For more information about this report, visit
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets